Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Dolutegravir Monotherapy for HIV No Longer Recommended

    Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

    09 January 2019 | Contagion Live
  • ‘RAPID’ HIV treatment initiation a success in San Francisco

    Populations considered hard to treat or engage in care can benefit from same-day antiretroviral treatment as part of a clinic offering social safety-net interventions.

    08 January 2019 | AVERT
  • Top 10 HIV Clinical Developments of 2018

    It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

    20 December 2018 | The Body Pro
  • Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults

    Scientists working to develop a cure for HIV infection sometimes need to conduct clinical trials in which participants are asked to temporarily interrupt ART, which contradicts the recommendations and guidelines for people with HIV under medical care.

    15 November 2018 | TAG
  • Dolutegravir Use During Pregnancy: What Are the Risks?

    Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

    22 October 2018 | Infectious Disease Advisor
  • ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

    ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

    16 September 2018 | ViiV press release
  • Focus on HIV-2 Infection: A Clinician Roundtable

    Infectious Disease Advisor interviewed the following experts to discuss the challenges and clinical implications pertaining to HIV-2.

    04 September 2018 | Infectious Disease Advisor
  • What you need to know about HIV two-drug regimens

    Integrase inhibitors—potent antiretrovirals that quickly and powerfully suppress HIV—have allowed HIV researchers and clinicians to explore dosing regimens that involve fewer than three or four drugs. Proponents of dual therapy say that effective regimens involving fewer drugs will lower costs, decrease pill burden and reduce the potential for drug-drug interactions and side effects. But is it that simple?

    28 August 2018 | BETA blog
  • Should Gilead Be Worried About This New Monthly HIV Medication?

    Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

    16 August 2018 | Motley Fool
  • Benefits, Risks of Dolutegravir Center Stage at AIDS 2018

    The integrase strand transfer inhibitor dolutegravir (Tivicay, GlaxoSmithKline) will be in the spotlight at the upcoming International AIDS Conference 2018.

    18 July 2018 | Medscape (requires free registration)
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.